go to medicines.ie homepage
Font Size
Search for:  
select
  Advanced Search

Alliance Pharmaceuticals Ireland
United Drug House, Magna Drive, Magna Business Park, Citywest Road, Dublin 24, Ireland
Telephone: + 44 (0)1249 466966
Fax: +44 (0)1249 466 977
Medical Information e-mail: medinfo@alliancepharma.co.uk
Summary of Product Characteristics last updated on medicines.ie: 02/12/2011
SPC Nu-Seals 300

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 02/12/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.1 - List of excipients
Date of revision of text on the SPC:   25-Nov-2011
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company


Changes/amendments highlighted in red text below:

2 Qualitative and Quantitative Composition



Each tablet contains:



Acetylsalicylic Acid Ph.Eur. (Aspirin) 300mg.





Excipients: also includes trace amounts of Ponceau 4R (E124)



For a full list of excipients see section 6.1.





6.1 List of Excipients



Maize Starch

Hypromellose

Talc

Methacrylic acid – ethyl acrylate (1:1) copolymer dispersion 30 per cent

Emulsion silicone

Polyethylene glycol 3350

Propylene glycol

Benzyl alcohol

Emulsion silicone

Edible pPrinting ink containing Ponceau 4R (E124) shellac, iron oxide (E172), isopropyl alcohol, n-butyl alcohol, propylene glycol, ammonium hydroxide (E527) and simeticone



 
Updated on 23/04/2009 and displayed until 02/12/2011
Reasons for adding or updating:
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.1 - Pharmacodynamic properties
Date of revision of text on the SPC:   04/2009
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company
Section 4.5 Now includes the folowing text
Ibuprofen: Experimental data suggest that ibuprofen may inhibit the effect of low dose aspirin on platelet aggregation when they are dosed concomitantly. However, the limitations of these data and the uncertainties regarding extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 5.1).
 
 
Section 5.1 Now includes the folowing text

Experimental data suggest that ibuprofen may inhibit the effect of low dose aspirin on platelet aggregation when they are dosed concomitantly. In one study, when a single dose of ibuprofen 400mg vas taken within 8 h before or within 30 min after immediate release aspirin dosing (81mg), a decreased effect of aspirin on the formation of thromboxane or platelet aggregation occurred. However, the limitations of these data and the uncertainties regarding extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use.
Updated on 08/11/2007 and displayed until 23/04/2009
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
Date of revision of text on the SPC:   08/2007
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company
Change to section 1 - trade name,
Change to section 2 - qualitative and quantitative composition,
Change to section 4.2 - Posology and Method of Administration,
Change to section 4.3 - Contra-indications,
Change to section 4.4 - Special Warnings and Precautions for Use,
Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction,
Change to section 4.6 - Pregnancy and Lactation,
Change to section 4.8 - Undesirable Effects,
Change to section 4.9 - Overdose,
Change to section 5.1 - Pharmacodynamic Properties,
Change to section 6.1 - List of Excipients
Updated on 04/09/2007 and displayed until 08/11/2007
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.1 - List of excipients
Date of revision of text on the SPC:   08/2007
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company
Section 1: Now reads Nu-Seals Gastro Resistant tablets
Section 2: Now reads

Each tablet contains:

Acetylsalicylic Acid Ph.Eur. (Aspirin) 300mg.


Excipients: also includes trace amounts of Ponceau 4R (E124)
For a full list of excipients see section 6.1.
 
Section 3: Now reads
Gastro-resistant tablets, white in colour, printed with ‘300’ in red.
 
Section 6.1: Now reads
Edible printing ink containing Ponceau 4R, E124.
 
Section 6.4: Now reads
 
Do not store above 25°C.  Keep containers tightly closed.
 
Updated on 06/08/2004 and displayed until 04/09/2007
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
Updated on 05/08/2004 and displayed until 06/08/2004
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
Updated on 23/06/2003 and displayed until 05/08/2004
Reasons for adding or updating:
  • New SPC for medicines.ie

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
  Aspirin